Notice NOT-OD-22-201 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-027 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-290 from the NIH Guide for Grants and Contracts

Notice NOT-AT-22-028 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-229 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support an established research resource program to serve the biomedical research community aimed at the collection, identification, staging, and distribution of conceptal tissues for use in studies to understand the underlying developmental biology of normal and abnormal human development as well as human pathologies.

Funding Opportunity RFA-DA-23-056 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure. This FOA will also support mechanistic studies of persistent or delayed pathophysiological effects after acute exposure to UPS opioids.

Funding Opportunity RFA-DA-23-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that will establish validated virtual measures of sociocultural, biobehavioral and environmental mechanisms that underlie trajectories of substance use, substance use exposures, and substance use disorders.

Funding Opportunity RFA-DA-23-055 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that will establish validated virtual measures of sociocultural, biobehavioral and environmental mechanisms that underlie trajectories of substance use, substance use exposures, and substance use disorders.

Funding Opportunity RFA-AT-23-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support multi-site clinical trials in geographically diverse school settings to test the efficacy or effectiveness of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) to promote mental, emotional, and behavioral (MEB) health and prevent MEB disorders among youth. The overall goal of this FOA is to provide support for a set of multisite trials to improve the evidence base of complementary and integrative health approaches that can be delivered in a school-based setting or with students to address the youth mental health crisis. Awards made under this FOA will support a milestone-driven planning phase (UG3) for one year with possible transition to a study conduct phase (UH3) of up to an additional four years. Total duration of the award will be a maximum of 5 years. Only UG3 projects that meet the scientific milestones and feasibility requirements will transition to the UH3phase. The UG3/UH3 application must be submitted as a single application describing both phases and instructed in this FOA.

Notice NOT-OH-22-006 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-22-238 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single-Year and Multiple-Year Conference grant programs (R13). AHRQ seeks to support conferences that help further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure the evidence is understood and used (http://www.ahrq.gov/funding/policies/foaguidance/index.html).

Notice NOT-CA-22-120 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-228 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions. To this end, the central goal of this initiative is to develop robust research programs that will explore how genes, environment, and host factors such as hormonal status (gonadal and brain-derived) interact at various levels of biologic complexity (i.e., cell, tissue, organs/organ systems, and populations) to produce heterogeneous phenotypes of disease risk and responsiveness to prevention/therapy in AD/ADRD.

Funding Opportunity RFA-NS-22-061 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications from established investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of traumatic brain injury (TBI) as a risk factor for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This funding opportunity encourages applications for short-term (2 yrs.) mentored career enhancement awards to further understand TBI as a risk factor for AD/ADRD. Two categories of candidates are targeted: (a) established TBI investigators who seek training with senior dementia researchers, and (b) established dementia researchers who seek training with senior TBI investigators.

Notice NOT-DK-22-024 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-099 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-199 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-022 from the NIH Guide for Grants and Contracts. *Note to ICs: Please do not join this announcement. Shared Interest must be completed systematically but the Type 4 submission is for NS R37 applications only. The National Institute of Neurological Disorders and Stroke (NINDS) Javits Neuroscience Investigator Award (R37) provides extended grant support to investigators with a history of exceptional performance and outstanding productivity. The objective of the NINDS Javits Award is to allow Javits awardees to obtain up to seven years of support in two segments: The initial phase of up to four years, and a second phase, providing an additional three years of support. This funding opportunity announcement is specifically for currently funded NINDS Javits recipients to request the second phase of the R37 award.

Funding Opportunity RFA-CA-22-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of a Data Management and Coordinating Center (DMCC, to be supported by this U24 FOA) and several Translational Research Centers (TRCs, to be supported by the companion U01 FOA, RFA-CA-22-031). The TRCs will conduct studies to improve the surveillance of liver cancer in high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer. The DMCC will support the TRCs and coordinate trans-Consortium activities with the following specific responsibilities: (1) Overall administrative and logistical coordination for the Liver Cancer Consortium; (2) Support for Consortium collaborative research studies and biospecimen collections, including protocol development, data processing, statistical support, and computational analysis; and (3) Consortium data management, including developing and maintaining an integrated database of research data generated by the consortium, as well as management of all data relevant to biospecimens used in TRC studies (including clinical data annotations, and specimen usage tracking). To achieve these goals, the DMCC is expected to provide multi-disciplinary expertise in liver cancer research, biomarkers for cancer detection, biostatistics, bioinformatics, and the information technology infrastructure to support data management for the Consortium.